Patrick Julier

OCTRU Head of Programming

I have over 25 years’ experience in the IT industry, working in manufacturing, finance, telecommunications and the public sector before working in Clinical Trials when I joined the Oncology Clinical Trials Office (OCTO) in 2004.

I am OCTRU's Head of Programming and lead a team of 5 programmers/database officers. I joined OCTRU in October 2013 when we had no IT systems to speak of. Since then we have developed 5 systems and installed and support 4 off-the-shelf systems.

We look forward to taking these systems forward and to continue providing a responsive and professional service to all the Clinical Trials Units within the OCTRU family.

Recent publications

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial.
Journal article

Kerr RS. et al, (2016), The lancet. oncology, 17, 1543 - 1557
A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS.
Journal article

Rosmarin D. et al, (2015), Gut, 64, 111 - 120
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial.
Journal article

Dutton SJ. et al, (2014), The lancet. oncology, 15, 894 - 904
Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.
Journal article

Rosmarin D. et al, (2014), Journal of clinical oncology : official journal of the american society of clinical oncology, 32, 1031 - 1039
Phase II clinical trial of six mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumors.
Journal article

Nicum S. et al, (2013), Journal of clinical oncology, 31

More publications